Geovax Labs Inc (GOVX) 0.2270 $GOVX
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
ACCESSWIRE - Thu Aug 07, 8:18AM CDT
ATLANTA, GA / ACCESSWIRE / August 7, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six months ended June 30, 2014 and provided a clinical development update.
GeoVax Announces Clinical Development License Agreement with Valneva SE
ACCESSWIRE - Wed Aug 06, 7:15AM CDT
Use of Valneva's EB66(R) Cell Line to Aid in Development of Commercial-Scale Manufacturing Process for GeoVax's HIV/AIDS Vaccine
VALNEVA enters into clinical development license agreement with GeoVax
M2 - Wed Aug 06, 5:32AM CDT
Biotechnology company Valneva SE announced on Wednesday that it has executed a clinical development license agreement to develop MVA-based vaccines in its EB66 vaccine production cell line.
GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
ACCESSWIRE - Wed Jul 16, 8:17AM CDT
Atlanta, GA / ACCESSWIRE / July 16, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant entitled "Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine." The grant award of approximately $290,000 is for the second year of a two-year project period.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Marketwire - Wed Mar 19, 10:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today the publication of the results of a study in which non-human primates vaccinated with simian prototypes of its HIV vaccine resisted up to 41 rectal exposures to simian immunodeficiency virus (SIV). The article, titled "Local Control of Repeated Rectal Challenges in DNA/MVA Vaccinated Macaques Protected Against a 1st Series of SIV Challenges" was published on-line in the Journal of Virology. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24574408. The print version will be available in May.
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients
Marketwire - Mon Jan 13, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion. The Company expects to release additional results from this trial as final analyses are completed, and in conjunction with scientific presentations and publications.
Immunomedics (IMMU) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:25AM CST
Immunomedics was a big mover last session, with shares rising over 10%.
Best's Rating Notification - Cincinnati Specialty Underwriters Ins Co
Rating Division - AMBest - Thu Dec 19, 1:31PM CST
A.M. Best Company has made the following rating update:
Athersys (ATHX) in Focus: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 7:32AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
OTC Signal Daily Stock Watch - GeoVax Labs, Inc.. (OTCQB: GOVX)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
HIV-1 Infection - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs2x4k/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2013" report to their offering. 'HIV-1 Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. Scope - A snapshot of the global therapeutic scenario for HIV-1 Infection. - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. United Biomedical, Inc. Aphios Corporation Pfizer Inc. Koronis Pharmaceuticals, Inc. Crucell N.V. GeoVax Labs, Inc. Enzo Biochem, Inc. ConjuChem Biotechnologies Inc. Critical Outcome Technologies Inc. Takara Bio Inc. Functional Genetics, Inc. Nutri Pharma ASA Quantum Pharmaceuticals Italfarmaco S.p.A. Statens Serum Institut and much more... For more information visit http://www.researchandmarkets.com/research/fs..._infection About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
ACCESSWIRE - Thu Aug 07, 8:18AM CDT
ATLANTA, GA / ACCESSWIRE / August 7, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six months ended June 30, 2014 and provided a clinical development update.
GeoVax Announces Clinical Development License Agreement with Valneva SE
ACCESSWIRE - Wed Aug 06, 7:15AM CDT
Use of Valneva's EB66(R) Cell Line to Aid in Development of Commercial-Scale Manufacturing Process for GeoVax's HIV/AIDS Vaccine
VALNEVA enters into clinical development license agreement with GeoVax
M2 - Wed Aug 06, 5:32AM CDT
Biotechnology company Valneva SE announced on Wednesday that it has executed a clinical development license agreement to develop MVA-based vaccines in its EB66 vaccine production cell line.
GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
ACCESSWIRE - Wed Jul 16, 8:17AM CDT
Atlanta, GA / ACCESSWIRE / July 16, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant entitled "Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine." The grant award of approximately $290,000 is for the second year of a two-year project period.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Marketwire - Wed Mar 19, 10:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today the publication of the results of a study in which non-human primates vaccinated with simian prototypes of its HIV vaccine resisted up to 41 rectal exposures to simian immunodeficiency virus (SIV). The article, titled "Local Control of Repeated Rectal Challenges in DNA/MVA Vaccinated Macaques Protected Against a 1st Series of SIV Challenges" was published on-line in the Journal of Virology. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24574408. The print version will be available in May.
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients
Marketwire - Mon Jan 13, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion. The Company expects to release additional results from this trial as final analyses are completed, and in conjunction with scientific presentations and publications.
Immunomedics (IMMU) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:25AM CST
Immunomedics was a big mover last session, with shares rising over 10%.
Best's Rating Notification - Cincinnati Specialty Underwriters Ins Co
Rating Division - AMBest - Thu Dec 19, 1:31PM CST
A.M. Best Company has made the following rating update:
Athersys (ATHX) in Focus: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 7:32AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
OTC Signal Daily Stock Watch - GeoVax Labs, Inc.. (OTCQB: GOVX)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
HIV-1 Infection - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs2x4k/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2013" report to their offering. 'HIV-1 Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. Scope - A snapshot of the global therapeutic scenario for HIV-1 Infection. - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. United Biomedical, Inc. Aphios Corporation Pfizer Inc. Koronis Pharmaceuticals, Inc. Crucell N.V. GeoVax Labs, Inc. Enzo Biochem, Inc. ConjuChem Biotechnologies Inc. Critical Outcome Technologies Inc. Takara Bio Inc. Functional Genetics, Inc. Nutri Pharma ASA Quantum Pharmaceuticals Italfarmaco S.p.A. Statens Serum Institut and much more... For more information visit http://www.researchandmarkets.com/research/fs..._infection About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
